ArticleBMJ open2019

Lost cost savings to the NHS in England due to the delayed entry of multiple generic low-dose transdermal buprenorphine: a case scenario analysis.

Stephen Robert Chapman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.